enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Atezolizumab - Wikipedia

   en.wikipedia.org/wiki/Atezolizumab

   Atezolizumab, sold under the brand name Tecentriq among others, is a monoclonal antibody medication used to treat urothelial carcinoma, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), hepatocellular carcinoma and alveolar soft part sarcoma, [9] [11] but discontinued for use in triple-negative breast cancer (TNBC). [12]

3. Atezolizumab/hyaluronidase - Wikipedia

   en.wikipedia.org/wiki/Atezolizumab/hyaluronidase

   The subcutaneous injection of atezolizumab and hyaluronidase was evaluated in IMscin001 (NCT03735121), an open-label, multi-center, international, randomized trial in adults with locally advanced or metastatic non-small cell lung cancer who were not previously exposed to cancer immunotherapy and who had disease progression following treatment with platinum-based chemotherapy. [2]

4. PD-1 and PD-L1 inhibitors - Wikipedia

   en.wikipedia.org/wiki/PD-1_and_PD-L1_inhibitors

   Atezolizumab (Tecentriq) is a fully humanised IgG1 (immunoglobulin 1) antibody developed by Roche Genentech. In 2016, the FDA approved atezolizumab for urothelial carcinoma and non-small cell lung cancer. Avelumab (Bavencio) is a fully human IgG1 antibody developed by Merck Serono and Pfizer.

5. Why Is Cancer Focused Tempest Therapeutics Stock Trading ...

   www.aol.com/why-cancer-focused-tempest...

   The company entered into an agreement with Roche Holdings AG (OTC:RHHBY) to advance the evaluation of amezalpat (TPST-1120) in combination with atezolizumab (Tecentriq) and bevacizumab, the ...

6. Roche's Tecentriq Combo Study Meets Co-Primary Endpoint - AOL

   www.aol.com/news/roche-apos-tecentriq-combo...

   Roche's (RHHBY) phase III study, evaluating a combination of Tecentriq and Avastin plus carboplatin and paclitaxel for first line treatment of advanced lung cancer met its co-primary endpoint of ...

7. Cancer immunotherapy - Wikipedia

   en.wikipedia.org/wiki/Cancer_immunotherapy

   Atezolizumab, sold under the brand name Tecentriq among others, is a monoclonal antibody medication used to treat urothelial carcinoma, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), hepatocellular carcinoma and alveolar soft part sarcoma, [73] [74] but discontinued for use in triple-negative breast cancer (TNBC). [75]

8. Checkpoint inhibitor - Wikipedia

   en.wikipedia.org/wiki/Checkpoint_inhibitor

   Atezolizumab: Tecentriq Genentech/Roche PD-L1: 2016 bladder cancer, non-small cell lung cancer, breast cancer, small cell lung cancer, hepatocellular carcinoma, metastatic melanoma Avelumab: Bavencio Merck KGaA and Pfizer PD-L1: 2017 Merkel cell carcinoma, urothelial carcinoma, renal cell carcinoma Durvalumab: Imfinzi Medimmune/AstraZeneca PD ...

9. She amputated her arm due to a rare cancer. Her open ... - AOL

   www.aol.com/she-amputated-her-arm-due-122710009.html

   In late October, Eldiara Doucette found out she only had five days left with her arm. The 22-year-old's synovial sarcoma − a rare cancer that affects soft tissue − had returned. Her hospital's ...